Effectiveness of Neoadjuvant Chemotherapy in Cardioesophageal Junction Cancer

https://doi.org/10.51699/ajbci.v3i2.2108
Cardioesophageal junction cancer neoadjuvant chemotherapy FLOT regimen DCF regimen tumor regression pathological response Lavnikova criteria multimodal treatment

Authors

  • Yakhyo Sheraliyevich Independent Researcher (Doctoral Candidate), Bukhara State Medical Institute.
  • Abrorjon Ahmadjonovich Yusupbekov Deputy Director for Scientific Affairs, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology.
  • Gafur Normurodovich Saidov Director of the Bukhara Branch, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology.
  • Elyor Ergashboevich Juraev Thoracic Department Physician, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology.
  • Bekzod Boymatovich Usmonov Deputy Director for Clinical Affairs, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology.
  • Otabek Dilshodovich Tuychiev Thoracic Department Physician, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology.
Vol. 3 No. 2 (2026): American Journal of Bioscience and Clinical Integrity
Articles
February 28, 2026

Downloads

Neoadjuvant chemotherapy (NACT) plays an important role in the
multimodal treatment of cardioesophageal junction cancer (CEJC),
particularly in locally advanced stages. This study evaluated the clinical and
pathological effectiveness of neoadjuvant chemotherapy administered
according to FLOT and DCF regimens in patients with stage IIIb–IVa disease.
Forty-seven patients received 4–6 cycles of chemotherapy, and treatment
response was assessed using MSCT or PET-CT imaging and repeat
histological examination. Overall treatment response was achieved in 87.2%
of patients, including complete regression in 19.1% and partial regression in
68.0% of cases. Pathological response assessment according to Lavnikova’s
criteria demonstrated grade III–IV therapeutic pathomorphosis in 12.8% of
patients. Although adverse effects were observed in 59.4% of cases, severe
toxicity (grade III) was rare and manageable. The findings confirm the
clinical effectiveness of neoadjuvant chemotherapy in locally advanced
cardioesophageal junction cancer, while indicating its partial but not
definitive impact on tumor regression.